Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buzaid, A. C.
Right arrow Articles by Benjamin, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buzaid, A. C.
Right arrow Articles by Benjamin, R. S.

Journal of Clinical Oncology, Vol 15, 1039-1051, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system

AC Buzaid, MI Ross, CM Balch, S Soong, WH McCarthy, L Tinoco, P Mansfield, JE Lee, A Bedikian, O Eton, C Plager, N Papadopoulos, SS Legha and RS Benjamin
Department of Melanoma/Sarcoma and Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. antoniovbuzaid@melvsarc.mda.uth.tmc.edu

PURPOSE: To critically review the accuracy of the current American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma and propose a more useful staging system. METHODS: Retrospective evaluation of the published data as well as a reanalysis of the University of Alabama and Sydney Melanoma Unit (UAB/SMU) data bases (n = 4,568) for patients with primary melanoma was performed to examine specifically the impact of level of invasion and ulceration on the prognostic value of tumor thickness. In addition, an overlay graphic technique was used to compare the Kaplan-Meier survival curves of patients with local recurrences, satellites, in-transit metastases, and nodal metastases reported in the literature. RESULTS: Tumor thickness and ulceration remained the most powerful prognostic indicators in patients with stage I and II disease. Level of invasion provided statistically significant prognostic information only in the subgroup of patients with tumor thickness < or = 1 mm, but the absolute 10-year survival differences were small and inconsistent (level II, 95%; level III, 85%; level IV, 89%). The best statistical fit for tumor thickness cutoffs was at 1 versus 2 versus 4 mm. The overlay graphic technique showed that patients who developed satellite lesions or local recurrence had prognoses similar to those of patients with stage III disease. The most important prognostic factor for patients with nodal metastases was number of involved nodes rather than size. CONCLUSION: Our analysis showed that the current AJCC staging system has many inaccuracies that should be modified to conform to published data. On the basis of our analysis and review of the literature, we propose a new and more accurate staging system.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
B. Badgwell, Y. Xing, J. E. Gershenwald, J. E. Lee, P. F. Mansfield, M. I. Ross, and J. N. Cormier
Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma
Ann. Surg. Oncol., October 1, 2007; 14(10): 2867 - 2875.
[Abstract] [Full Text] [PDF]

Home page
 J. Nucl. Med. Technol.Home page
M. V. Mar, S. A. Miller, E. E. Kim, and H. A. Macapinlac
Evaluation and Localization of Lymphatic Drainage and Sentinel Lymph Nodes in Patients with Head and Neck Melanomas by Hybrid SPECT/CT Lymphoscintigraphic Imaging
J. Nucl. Med. Technol., March 1, 2007; 35(1): 10 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. M. Swetter, S. Soon, C. R. Harrington, and S. C. Chen
Effect of Health Care Delivery Models on Melanoma Thickness and Stage in a University-Based Referral Center: An Observational Pilot Study
Arch Dermatol, January 1, 2007; 143(1): 30 - 36.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Cascinelli, E. Bombardieri, R. Bufalino, T. Camerini, A. Carbone, C. Clemente, L. Lenisa, L. Mascheroni, A. Maurichi, E. Pennacchioli, et al.
Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival
J. Clin. Oncol., September 20, 2006; 24(27): 4464 - 4471.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Thomas
Time to Re-Evaluate Sentinel Node Biopsy in Melanoma Post-Multicenter Selective Lymphadenectomy Trial
J. Clin. Oncol., December 20, 2005; 23(36): 9443 - 9444.
[Full Text] [PDF]

Home page
 Integr Cancer TherHome page
D. Nathan
Medical Oncology
Integr Cancer Ther, September 1, 2005; 4(3): 251 - 253.
[PDF]

Home page
 Arch DermatolHome page
L. Shaikh, R. W. Sagebiel, C. M. M. Ferreira, M. Nosrati, J. R. Miller III, and M. Kashani-Sabet
The Role of Microsatellites as a Prognostic Factor in Primary Malignant Melanoma
Arch Dermatol, June 1, 2005; 141(6): 739 - 742.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Voit, M. Kron, J. Rademaker, M. Schwurzer-Voit, W. Sterry, L. Weber, C. Ozdemir, T. Proebstle, and U. Keilholz
Molecular Staging in Stage II and III Melanoma Patients and Its Effect on Long-Term Survival
J. Clin. Oncol., February 20, 2005; 23(6): 1218 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
P. Saiag, M. Bernard, A. Beauchet, M.-L. Bafounta, I. Bourgault-Villada, and S. Chagnon
Ultrasonography Using Simple Diagnostic Criteria vs Palpation for the Detection of Regional Lymph Node Metastases of Melanoma
Arch Dermatol, February 1, 2005; 141(2): 183 - 189.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. K. Eigentler, P. G. Buettner, U. Leiter, and C. Garbe
Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry
J. Clin. Oncol., November 1, 2004; 22(21): 4376 - 4383.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. B. Stitzenberg, P. A. Groben, S. L. Stern, N. E. Thomas, T. A. Hensing, L. B. Sansbury, and D. W. Ollila
Indications for Lymphatic Mapping and Sentinel Lymphadenectomy in Patients with Thin Melanoma (Breslow Thickness <=1.0 mm)
Ann. Surg. Oncol., October 1, 2004; 11(10): 900 - 906.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Leiter, P. G. Buettner, T. K. Eigentler, and C. Garbe
Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society
J. Clin. Oncol., September 15, 2004; 22(18): 3660 - 3667.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
C. M. Balch, S.-J. Soong, M. B. Atkins, A. C. Buzaid, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr., J. M. Kirkwood, et al.
An Evidence-based Staging System for Cutaneous Melanoma
CA Cancer J Clin, May 1, 2004; 54(3): 131 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. B. Francken, H. M. Shaw, J. F. Thompson, S.-j. Soong, N. A. Accortt, M. F. Azzola, R. A. Scolyer, G. W. Milton, W. H. McCarthy, M. H. Colman, et al.
The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up
Ann. Surg. Oncol., April 1, 2004; 11(4): 426 - 433.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kashani-Sabet, L. Shaikh, J. R. Miller III, M. Nosrati, C. M.M. Ferreira, R. J. Debs, and R. W. Sagebiel
NF-{kappa}B in the Vascular Progression of Melanoma
J. Clin. Oncol., February 15, 2004; 22(4): 617 - 623.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. W. Carlson, D. R. Murray, R. H. Lyles, C. A. Staley, A. Hestley, and C. Cohen
The Amount of Metastatic Melanoma in a Sentinel Lymph Node: Does It Have Prognostic Significance?
Ann. Surg. Oncol., June 1, 2003; 10(5): 575 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
J. B. Lowe, E. Hurst, J. F. Moley, and L. A. Cornelius
Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Arch Dermatol, May 1, 2003; 139(5): 617 - 621.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Garbe, A. Paul, H. Kohler-Spath, U. Ellwanger, W. Stroebel, M. Schwarz, B. Schlagenhauff, F. Meier, B. Schittek, H.-J. Blaheta, et al.
Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up Strategy
J. Clin. Oncol., February 1, 2003; 21(3): 520 - 529.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
M.-F. Demierre
Thin Melanomas and Regression, Thick Melanomas and Older Men: Prognostic Implications and Perspectives on Secondary Prevention
Arch Dermatol, May 1, 2002; 138(5): 678 - 682.
[Full Text] [PDF]

Home page
 JCOHome page
M. Kashani-Sabet, R. W. Sagebiel, C. M.M. Ferreira, M. Nosrati, and J. R. Miller III
Tumor Vascularity in the Prognostic Assessment of Primary Cutaneous Melanoma
J. Clin. Oncol., April 1, 2002; 20(7): 1826 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. L. Kilbridge, B. F. Cole, J. M. Kirkwood, F. G. Haluska, M. A. Atkins, J. C. Ruckdeschel, D. E. Sock, R. F. Nease Jr, and J. C. Weeks
Quality-of-Life-Adjusted Survival Analysis of High-Dose Adjuvant Interferon Alfa-2b for High-Risk Melanoma Patients Using Intergroup Clinical Trial Data
J. Clin. Oncol., March 1, 2002; 20(5): 1311 - 1318.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. Balch and M. C. Mihm
Reply to the article "The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group", by D. J. Ruiter et al. (Ann Oncol 2001; 12: 9-11)
Ann. Onc., January 19, 2002; 13(1): 175 - 176.
[Full Text] [PDF]

Home page
 JCOHome page
D. Bafaloukos, H. Gogas, V. Georgoulias, E. Briassoulis, G. Fountzilas, E. Samantas, Ch. Kalofonos, D. Skarlos, A. Karabelis, and P. Kosmidis
Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group
J. Clin. Oncol., January 15, 2002; 20(2): 420 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
M. Kashani-Sabet, R. W. Sagebiel, C. M. M. Ferreira, M. Nosrati, and J. R. Miller III
Vascular Involvement in the Prognosis of Primary Cutaneous Melanoma
Arch Dermatol, September 1, 2001; 137(9): 1169 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Balch, S.-J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, M. Urist, K. M. McMasters, M. I. Ross, J. M. Kirkwood, et al.
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
J. Clin. Oncol., August 15, 2001; 19(16): 3622 - 3634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Balch, A. C. Buzaid, S.-J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr, J. M. Kirkwood, et al.
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
J. Clin. Oncol., August 15, 2001; 19(16): 3635 - 3648.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. M. McMasters, D. S. Reintgen, M. I. Ross, J. E. Gershenwald, M. J. Edwards, A. Sober, N. Fenske, F. Glass, C. M. Balch, and D. G. Coit
Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement
J. Clin. Oncol., June 1, 2001; 19(11): 2851 - 2855.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Kirkwood, J. G. Ibrahim, J. A. Sosman, V. K. Sondak, S. S. Agarwala, M. S. Ernstoff, and U. Rao
High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801
J. Clin. Oncol., May 1, 2001; 19(9): 2370 - 2380.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. H. Kanzler and S. Mraz-Gernhard
Treatment of Primary Cutaneous Melanoma
JAMA, April 11, 2001; 285(14): 1819 - 1821.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. M. Karjalainen, R. H. Tammi, M. I. Tammi, M. J. Eskelinen, U. M. Agren, J. J. Parkkinen, E. M. Alhava, and V.-M. Kosma
Reduced Level of CD44 and Hyaluronan Associated with Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma
Am. J. Pathol., September 1, 2000; 157(3): 957 - 965.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Kirkwood, J. G. Ibrahim, V. K. Sondak, J. Richards, L. E. Flaherty, M. S. Ernstoff, T. J. Smith, U. Rao, M. Steele, and R. H. Blum
High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
J. Clin. Oncol., June 12, 2000; 18(12): 2444 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
D. M. Lipsker, G. Hedelin, E. Heid, E. M. Grosshans, and B. J. Cribier
Striking Increase of Thin Melanomas Contrasts With Stable Incidence of Thick Melanomas
Arch Dermatol, December 1, 1999; 135(12): 1451 - 1456.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Fujiwara, D. D. J. Chi, H. Wang, P. Keleman, D. L. Morton, R. Turner, and D. S. B. Hoon
Plasma DNA Microsatellites as Tumor-specific Markers and Indicators of Tumor Progression in Melanoma Patients
Cancer Res., April 1, 1999; 59(7): 1567 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Syngal and S. Kaptain
Case 7-1999- A 50-Year-Old Woman with Severe Diarrhea during Radiation Treatment for Resected Metastatic Melanoma
N. Engl. J. Med., March 11, 1999; 340(10): 789 - 796.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T.-J. Yao, M. Meyers, P. O. Livingston, A. N. Houghton, and P. B. Chapman
Immunization of Melanoma Patients with BEC2-Keyhole Limpet Hemocyanin plus BCG Intradermally Followed by Intravenous Booster Immunizations with BEC2 to Induce Anti-GD3 Ganglioside Antibodies
Clin. Cancer Res., January 1, 1999; 5(1): 77 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
J. N. Myers
Value of Neck Dissection in the Treatment of Patients With Intermediate-Thickness Cutaneous Malignant Melanoma of the Head and Neck
Arch Otolaryngol Head Neck Surg, January 1, 1999; 125(1): 110 - 115.
[Full Text] [PDF]

Home page
 Arch DermatolHome page
S. Mraz-Gernhard, R. W. Sagebiel, M. Kashani-Sabet, J. R. Miller III, and S. P. L. Leong
Prediction of Sentinel Lymph Node Micrometastasis by Histological Features in Primary Cutaneous Malignant Melanoma
Arch Dermatol, August 1, 1998; 134(8): 983 - 987.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. E. Lee, P. F. Mansfield, M. I. Ross, M. Pecherstorfer, and A. Keck
Cutaneous Melanoma Metastases
N. Engl. J. Med., March 26, 1998; 338(13): 922 - 923.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online